Concepedia

Stephanie Dodd

SD

15

Publications

1.8K

Citations

13

H-Index

2010

Active since

Affiliations

Novartis (United States)(Current)

Novartis (Switzerland)

Novartis Institutes for BioMedical Research

Amgen (United States)

AstraZeneca (United Kingdom)

Stephanie Dodd is an author at Novartis (United States) specializing in drug discovery, medicine, and pharmacology.

Top concepts

MedicineDrug DiscoveryPharmacologyHealthNutritionEngineeringFood SafetyBiochemistryPublic HealthTumor Biology

Publications per year

2010–2023

15

Publications

15

The allosteric inhibitor ABL001 enables dual targeting of BCR–ABL1

Andrew A. Wylie, Joseph Schoepfer, Wolfgang Jahnke et al. · Nature · 2017 · 574 citations

Molecular Pharmacology, Drug Target, Medicine +3

Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1

Joseph Schoepfer, Wolfgang Jahnke, Giuliano Berellini et al. · Journal of Medicinal Chemistry · 2018 · 432 citations · Full text

Drug Target, Mixed-phenotype Acute Leukemia, Molecular Biology +16

Discovery of NVP-LDE225, a Potent and Selective Smoothened Antagonist

Shifeng Pan, Xu Wu, Jiqing Jiang et al. · ACS Medicinal Chemistry Letters · 2010 · 325 citations · Full text

Selective Smoothened Antagonist, Chemoprevention Strategy, Novel Therapy +14

Discovery and Evaluation of Clinical Candidate IDH305, a Brain Penetrant Mutant IDH1 Inhibitor

Young Shin Cho, Julian Levell, Gang Liu et al. · ACS Medicinal Chemistry Letters · 2017 · 113 citations · Full text

Use of Physiologically Based Pharmacokinetic (PBPK) Modeling for Predicting Drug-Food Interactions: an Industry Perspective

Arian Emami Riedmaier, Kevin DeMent, James E. Huckle et al. · The AAPS Journal · 2020 · 93 citations · Full text

Rows per page

1–5 of 15